Compare Charles River Laboratories Intl. Inc (CRL) vs Manhattan Associates Inc (MANH) Price & Performance

Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.

While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.

MANH trades at $191.05, down 2.37% on the day, but maintains a bullish technical outlook with strong moving average signals and support near $192. The company reported robust Q2 2026 earnings, beating EPS estimates with $1.39 versus $1.32 expected, driven by 26% cloud revenue growth. However, a legal investigation into fiduciary duties by Rosen Law Firm presents a headwind. Analyst consensus remains strongly bullish with a $210.33 price target and 80% buy ratings.

The stock offers upside potential from consistent earnings beats and cloud momentum, but faces risks from the ongoing legal probe and elevated valuation multiples. Net income is projected to dip slightly in 2026, necessitating careful monitoring of execution against guidance. The current price sits just above key support, with resistance at $199.